Key takeaway
In 9,170 older white men from four cohorts, sarcopenia affected only 1.1% (EWGSOP2), 1.7% (SDOC) or 5.3% (modified SDOC), the definitions agreed poorly (kappa = 0.17), yet each was linked to higher mortality (HR 1.76, 2.75 and 1.93). The cohorts were white men only, and sarcopenia was linked to death but not shown to cause it.
Study design
Observational meta-analysis
Reading basis
Published abstract
Reading focus
Design & applicability
The research question
Two new sarcopenia definitions, from the European Working Group (EWGSOP2) and the Sarcopenia Definitions and Outcomes Consortium (SDOC), use different thresholds, and little was known about how many people they flag, whether they agree, and how well they predict death. The authors compared them across several large cohorts.
Who and how
Pooled analysis of white men from four cohorts: Health ABC, MrOS (Sweden and USA), the Hertfordshire Cohort Study and SarcoPhAge. Appendicular lean mass was measured by DXA, grip strength by dynamometer, and usual gait speed over 2.4-6 m. EWGSOP2 was grip strength below 27 kg and lean mass index below 7.0 kg/m2; SDOC was grip strength below 35.5 kg and gait speed below 0.8 m/s; modified SDOC used gait speed below 1.0 m/s. Agreement was assessed with Cohen's kappa. Mortality was analyzed with Cox regression adjusted for age and weight, pooled by random-effects meta-analysis.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Participants (n = 9,170) had a mean age of 74.3 years (SD 4.9); 5,929 died during mean follow-up of 12.1 years (SD 5.5).
- 2Sarcopenia prevalence was 1.1% by EWGSOP2, 1.7% by SDOC and 5.3% by modified SDOC.
- 3Agreement between EWGSOP2 and SDOC was weak (kappa = 0.17).
- 4Compared with no sarcopenia, pooled mortality hazard ratios were 1.76 (95% CI 1.42-2.18) for EWGSOP2, 2.75 (2.28-3.31) for SDOC and 1.93 (1.54-2.41) for modified SDOC. Heterogeneity was I2 0.0% for the first two and 58.3% for modified SDOC.
Limits & uncertainty
- 1Only white men were included, so results may not apply to women or other ethnic groups.
- 2Prevalence was low (1.1% to 5.3%), so the sarcopenia groups were small relative to the total, even though statistically clear.
- 3Mortality models adjusted only for age and weight, so other health differences may explain part of the links.
- 4The cohorts used different gait courses (2.4-6 m), which may add some inconsistency.
What to take from it
The same man could be called sarcopenic under one definition and not another, so a label alone is not a reliable guide. Weak grip and slow walking, however, were tied to higher mortality across cohorts. If you worry about strength or mobility, ask your clinician to assess you.
Reading your own data
Gait speed and strength are the components that matter here. A wearable can offer a rough walking-pace trend, but it does not measure grip strength or lean mass by DXA. Compare your own pace over the same route and device across months.
How to read this evidence
Pooling observational studies does not remove their confounding. Check overlapping cohorts and whether relative effects are being confused with absolute benefits.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background
The 2019 European Working Group on Sarcopenia in Older People (EWGSOP2) and the Sarcopenia Definitions and Outcomes Consortium (SDOC) have recently proposed sarcopenia definitions. However, comparisons of the performance of these approaches in terms of thresholds employed, concordance in individuals and prediction of important health-related outcomes such as death are limited. We addressed this in a large multinational assembly of cohort studies that included information on lean mass, muscle strength, physical performance and health outcomes.
Methods
White men from the Health Aging and Body Composition (Health ABC) Study, Osteoporotic Fractures in Men (MrOS) Study cohorts (Sweden, USA), the Hertfordshire Cohort Study (HCS) and the Sarcopenia and Physical impairment with advancing Age (SarcoPhAge) Study were analysed. Appendicular lean mass (ALM) was ascertained using DXA; muscle strength by grip dynamometry; and usual gait speed over courses of 2.4-6 m. Deaths were recorded and verified. Definitions of sarcopenia were as follows: EWGSOP2 (grip strength <27 kg and ALM index <7.0 kg/m^(2) ), SDOC (grip strength <35.5 kg and gait speed <0.8 m/s) and Modified SDOC (grip strength <35.5 kg and gait speed <1.0 m/s). Cohen's kappa statistic was used to assess agreement between original definitions (EWGSOP2 and SDOC). Presence versus absence of sarcopenia according to each definition in relation to mortality risk was examined using Cox regression with adjustment for age and weight; estimates were combined across cohorts using random-effects meta-analysis.
Results
Mean (SD) age of participants (n = 9170) was 74.3 (4.9) years; 5929 participants died during a mean (SD) follow-up of 12.1 (5.5) years. The proportion with sarcopenia according to each definition was EWGSOP2 (1.1%), SDOC (1.7%) and Modified SDOC (5.3%). Agreement was weak between EWGSOP2 and SDOC (κ = 0.17). Pooled hazard ratios (95% CI) for mortality for presence versus absence of each definition were EWGSOP2 [1.76 (1.42, 2.18), I^(2) : 0.0%]; SDOC [2.75 (2.28, 3.31), I^(2) : 0.0%]; and Modified SDOC [1.93 (1.54, 2.41), I^(2) : 58.3%].
Conclusions
There was low prevalence and poor agreement among recent sarcopenia definitions in community-dwelling cohorts of older white men. All indices of sarcopenia were associated with mortality. The strong relationship between sarcopenia and mortality, regardless of the definition, illustrates that identification of appropriate management and lifecourse intervention strategies for this condition is of paramount importance.
Sources & attribution
Recent sarcopenia definitions-prevalence, agreement and mortality associations among men: Findings from population-based cohorts.
Westbury LD, Beaudart C, Bruyère O, Cauley JA, Cawthon P, Cruz-Jentoft AJ, Curtis EM, Ensrud K, Fielding RA, Johansson H, Kanis JA, Karlsson MK, Lane NE, Lengelé L, Lorentzon M, McCloskey E, Mellström D, Newman AB, Ohlsson C, Orwoll E, Reginster JY, Ribom E, Rosengren BE, Schousboe JT, Shiroma EJ, Harvey NC, Dennison EM, Cooper C, International Musculoskeletal Ageing Network.
Journal of cachexia, sarcopenia and muscle · 2023-01-05
DOI: 10.1002/jcsm.13160 ↗PubMed · 36604970 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
ACSM review of 137 reviews: resistance training works, and few programme details matter
The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.
Medicine & Science in Sports & Exercise
Nearly every resistance training plan beat no exercise; heavy loads led for strength
In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.
British Journal of Sports Medicine
Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes
Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.
British Journal of Sports Medicine
Protein supplements and weight training: small extra gains, smaller in older adults
Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.
British Journal of Sports Medicine

